Achieving good glycemic control: Initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California diabetes registry

American Journal of Managed Care

Volumn 11, Issue 4, 2005, Pages 262-270

  Karter, Andrew J ^a   Moffet, Howard H ^a   Liu, Jennifer ^a   Parker, Melissa M ^a   Ahmed, Ameena T ^a   Ferrara, Assiamira ^a   Selby, Joe V ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BEHAVIOR; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DIABETES CONTROL; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE DELIVERY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; REGISTER; TREATMENT OUTCOME;

AGED; CALIFORNIA; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGISTRIES; TREATMENT OUTCOME;

EID: 17644420308     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care. 1987;10:1-19.
2. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
3. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care. 2003;26:1852-1855.
4. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-372.
5. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996;156:259-264.
6. American Diabetes Association. Clinical practice recommendations. 1999. Diabetes Care. 1999;22(suppl 1).
7. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703-710.
8. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001;111:1-9.
9. Hiatt RA, Friedman GD. Characteristics of patients referred for treatment of end-stage renal disease in a defined population. Am J Public Health. 1982;72:829-833.
10. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287:2519-2527.
11. Karter AJ, Parker MM, Moffet HH, et al. Missed appointments and poor glycemic control: an opportunity to identify high-risk diabetic patients. Med Care. 2004;42:110-115.
12. Selby JV, Karter AJ, Ackerson LM, Ferrara A, Liu J. Developing a prediction rule from automated clinical databases to identify high-risk patients in a large population with diabetes. Diabetes Care. 2001;24:1547-1555.
13. Karter AJ, Ferrara A, Darbinian J, Ackerson LM, Selby JV. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care. 2000;23:477-483.
14. Karter AJ, Ahmed AT, Liu J, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Response to Delea et al. Diabetes Care. 2004;27:850-851.
15. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920.
16. Bristol-Myers Squibb Company. Glucophage (metformin hydrochloride) tablets. Prescribing information [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2004.
17. Rothman KJ, Greenland S. Modern Epidemiology. 1st ed. Philadelphia, Pa: Lippincott-Raven; 1998.
18. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149:981-983.
19. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
20. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336.
21. Kramer MS, Shapiro SH. Scientific challenges in the application of randomized trials. JAMA. 1984;252:2739-2745.
22. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1992;268:1417-1422.
23. Riegelman R, Verme D, Rochon J, El-Mohandes A. Interaction and intervention modeling: predicting and extrapolating the impact of multiple interventions. Ann Epidemiol. 2002;12:151-156.
24. Robin DM, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794-811.
25. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825-834.
26. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care. 2001;24:1411-1415.
27. Colwell JA. Controlling type 2 diabetes: are the benefits worth the costs? JAMA. 1997;278:1700.
28. DiTusa L, Luzier AB, Jarosz DE, Snyder BD, Izzo JLJ. Treatment of hypertension in a managed care setting. Am J Manag Care. 2001;7:520-524.
29. Cheng JW, Kalis MM, Feifer S. Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy. 2001;21:828-841.
30. Thijs L, Staessen JA, Beleva S, et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med. 2001;2:298-306.
31. Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Am J Cardiol. 2001;87:554-559.
32. Chung N, Cho SY, Choi DH, et al. STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target. Clin Ther. 2001;23:858-870.
33. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-1702.
34. Poses RM, Smith WR, McClish DK, Anthony M. Controlling for confounding by indication for treatment. Are administrative data equivalent to clinical data? Med Care. 1995;33:AS36-46.
35. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997;278:1663-1669.
36. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22:403-408.
37. Wolpert HA, Anderson BJ. Metabolic control matters: why is the message lost in the translation? The need for realistic goal-setting in diabetes care. Diabetes Care. 2001;24:1301-1303.
38. Delahanty LM, Halford BN. The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care. 1993;16:1453-1458.
39. Domenech MI, Assad D, Mazzei ME, Kronsbein P, Gagliardino JJ. Evaluation of the effectiveness of an ambulatory teaching/treatment programme for non-insulin dependent (type 2) diabetic patients. Acta Diabetol. 1995;32:143-147.
40. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-797.
41. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
42. Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications. Diabetes Care. 2002;25:S50-S60.
43. Van Dam RM, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Dietary patterns and risk for type 2 diabetes mellitus in US men. Ann Intern Med. 2002;136:201-209.
44. Surwit RS, van Tilburg MA, Zucker N, et al. Stress management improves long-term glycemic control in type 2 diabetes. Diabetes Care. 2002;25:30-34.
45. Cook CB, Ziemer DC, El-Kebbi IM, et al. Diabetes in urban African-Americans, XVI: overcoming clinical inertia improves glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:1494-1500.
46. Mottur-Pilson C, Snow V, Bartlett K. Physician explanations for failing to comply with "best practices." Eff Clin Pract. 2001;4:207-213.
47. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003;9:213-217.
48. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342-1349.